Thinking About an Alzheimer’s Blood Test? Here’s What You Should Know First
A few years ago, if someone asked me whether there was a blood test for Alzheimer’s disease, the answer was pretty simple: “No.”
Today, the answer is… well, it’s complicated.
That’s good news, but there remains quite a bit of confusion around the testing—for patients and healthcare providers alike. People are suddenly hearing terms like p-tau217, amyloid, and biomarkers without much explanation. I’ve had more than one patient tell me they left an appointment with another provider with the knowledge that they had a “positive biomarker,” but not really understanding what that actually meant.
Honestly, I understand why. We’ve introduced an entirely new way of thinking about Alzheimer’s disease in just a few years, and it feels like the language has changed almost overnight.
Blood tests that detect changes associated with Alzheimer’s disease have moved from research laboratories into clinical practice faster than many people realize. They’re exciting, and they may allow doctors to identify Alzheimer’s pathology earlier than ever before—often without immediately needing a costly PET scan or an invasive lumbar puncture.
Like almost everything else in medicine, these tests are powerful tools when used for the right patient, at the right time, and interpreted in the proper clinical context. Understanding what these tests can—and can’t—tell you will help you have a much more informed conversation with your healthcare provider.
What Is the Test Actually Measuring?
Before understanding what these tests measure, it’s important to understand what they don’t measure: Alzheimer’s blood tests aren’t looking for dementia. That may sound confusing. What they do measure is the biological changes associated with Alzheimer’s disease. Dementia is a clinical syndrome with many possible causes, and Alzheimer’s disease is simply the most common one.1
In Alzheimer’s disease, long before someone notices memory problems, changes have already been taking place inside the brain.2 Until recently, confirming these biological changes usually required either an amyloid PET scan or a lumbar puncture. Today, advances in laboratory technology allow many of these same biological signals to be measured with a simple blood draw.3
When p-tau217 (phosphorylated tau-217) levels rise in the blood, they are strongly associated with the biological changes seen in Alzheimer’s disease and correlate closely with the presence of amyloid protein pathology. Plasma p-tau217 is currently one of the highest-performing markers for identifying biologically defined Alzheimer’s disease.4
It’s a piece of the puzzle, but it is important to understand that the test isn’t measuring your memory or thinking ability. It’s measuring biology.
Think of it like a home smoke detector. When the alarm goes off, it doesn’t tell you whether a fire started in the kitchen, the garage, or if someone just burnt toast. It simply alerts you that something may be burning. Blood biomarkers work similarly. They don’t show us Alzheimer’s disease directly, but they tell us that something associated with Alzheimer’s biology deserves a closer look.
A clearly positive result from a validated assay suggests that Alzheimer’s biology is likely present in the brain. Having the biology of Alzheimer’s, however, is not the same thing as having the clinical disease.
We now know that some older adults carry amyloid plaques in their brains for years before symptoms ever appear, while others may never develop dementia during their lifetime.5 That’s why a laboratory result always has to be interpreted alongside a person’s real-world symptoms and physical examination. A positive test is a clue and a piece of the puzzle—not an automatic diagnosis.
What a Normal Result Actually Means
A clearly negative result from a well-validated test can make Alzheimer’s pathology much less likely. However, it does not prove that your brain is healthy or that your memory concerns are imaginary.
Because Alzheimer’s is only one cause of cognitive decline, a negative test simply points your medical team toward other potential drivers:
- Other Neurodegenerative Conditions: Conditions like Lewy body dementia or frontotemporal dementia affect thinking and behavior but do not show up on Alzheimer’s blood tests.
- Vascular Changes: Brain changes caused by small strokes or chronic damage to the brain’s blood vessels.
- Treatable Medical Issues: Vitamin B12 deficiencies, thyroid disease, or metabolic imbalances.
- Reversible Factors: Undiagnosed sleep apnea, chronic anxiety or depression, or side effects from common prescription medications.
A negative result isn’t a dead end—it’s vital information that helps your doctor search for the true root cause of your symptoms. Clinical judgment always takes priority: if a patient presents with classic, progressive symptoms of cognitive decline but has a negative blood test, a physician may recommend follow-up imaging or repeat testing over time.
Who Should (or Should Not) Be Tested?
One of the biggest questions in Alzheimer’s research is whether finding amyloid pathology before symptoms develop actually changes a person’s long-term outcome. Unlike high cholesterol or high blood pressure, we simply don’t know the answer yet. Several ongoing clinical trials are attempting to answer exactly that question.
Because of that uncertainty, routine Alzheimer’s blood biomarker screening is not recommended for cognitively healthy adults. Current recommendations focus on using these tests as part of the evaluation of people who are already experiencing persistent cognitive symptoms, particularly when the diagnosis is uncertain or when someone is being considered for anti-amyloid therapy.6
That said, not everyone being tested today has memory problems. Some people pursue testing through direct-to-consumer laboratories, while others participate in research studies designed to understand Alzheimer’s disease before symptoms develop.
If a cognitively normal person has an abnormal biomarker result, it does not mean they have Alzheimer’s disease, mild cognitive impairment, or that dementia is inevitable. It also does not tell us when—or even if—symptoms will develop.
On the other hand, I don’t think the conversation ends there. I’ve had patients tell me they’d rather know, even if the answers aren’t complete. Others have said they’d rather not. Neither perspective is wrong.
For some people, learning they have evidence of Alzheimer’s pathology might simply create anxiety. For others, it may finally provide the motivation to prioritize exercise, treat sleep apnea, improve their diet, or better manage conditions like diabetes and high blood pressure. Those lifestyle changes are worthwhile regardless of what a blood test shows. But for some people, knowing they have evidence of Alzheimer’s pathology becomes the push they needed to finally make them.
Whether that potential benefit outweighs the anxiety and uncertainty of knowing is a deeply personal decision.
Understanding Your Results: Why Not All Tests Are the Same
If your doctor orders an Alzheimer’s blood test, the name and format may vary. Patients often assume every laboratory measures exactly the same thing. Some tests measure p-tau217 by itself, while others combine multiple biomarkers into a proprietary algorithm that generates an amyloid probability score rather than reporting each biomarker individually. Other laboratories report individual biomarker values or different ratios instead.
Because these assays are not interchangeable, results from one laboratory should not be directly compared with those of another or interpreted using another company’s cutoffs. Your result should be interpreted using the validated thresholds and intended use of the specific test that was ordered, keeping in mind that overall health factors—such as reduced kidney function—can also affect biomarker concentrations.7
| Biomarker / Test Type | What It Reflects | Clinical Use |
|---|---|---|
| p-tau217 | Alzheimer’s-associated tau changes | One of the strongest individual blood biomarkers.4 |
| Aβ42/Aβ40 ratio | Brain amyloid plaque burden | Often combined with tau markers.8 |
| Composite Probability Scores | Combines multiple biomarkers | Estimates likelihood of amyloid pathology.8 |
| GFAP | Astrocyte activation and brain injury response | Supportive, but not specific to Alzheimer’s disease.9 |
| NfL | Injury to nerve-cell axons | Indicates neurodegeneration, but does not identify its cause.10 |
If a blood biomarker is positive, the evaluation usually doesn’t stop there. Your clinician still has to determine whether the result matches your symptoms, cognitive testing, and overall medical picture. In some cases, additional testing—such as an amyloid PET scan or cerebrospinal fluid analysis—may still be recommended before making a diagnosis or considering treatment.
The Bottom Line
Before ordering any medical test, ask a simple question: What will we do differently with the result? If that answer is clear, testing may be worthwhile. If the answer is, “I’m not sure,” it may be worth having another conversation first.
Twenty years ago, we couldn’t measure Alzheimer’s biology with a simple blood draw. Today we can. That’s one of the most significant advances we’ve seen in dementia care.
Alzheimer’s blood biomarkers are an exciting advance, but like every good diagnostic tool, they are most valuable when they are ordered for the right reason and interpreted in the right clinical context. A blood test can tell us whether Alzheimer’s biology may be present. It can’t tell us who you are, how you’re functioning, or where your story is headed. That’s why medicine is still practiced one person at a time—not one laboratory value at a time.
References
- Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0
- Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
- Hansson O, Blennow K, Zetterberg H, Dage JL. Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nat Aging. 2023;3(5):506-519. doi:10.1038/s43587-023-00403-3
- Therriault J, Brum WS, Hansson O, et al. Blood phosphorylated tau for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2025;24(9):740-752. doi:10.1016/S1474-4422(25)00227-3
- Jansen WJ, Ossenkoppele R, Tijms BM, et al; Amyloid Biomarker Study Group. Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry. 2018;75(1):84-95. doi:10.1001/jamapsychiatry.2017.3391
- Palmqvist S, Tampi MP, Carrillo MC, et al. Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimers Dement. 2025;21(2):e70535. doi:10.1002/alz.70535
- Zhang B, Zhang C, Wang Y, et al. Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer’s disease. Front Aging Neurosci. 2023;15:1150510. doi:10.3389/fnagi.2023.1150510
- Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81(3):255-263. doi:10.1001/jamaneurol.2023.5319
- Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain. 2021;144(11):3505-3516. doi:10.1093/brain/awab223
- Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870-881. doi:10.1136/jnnp-2018-320106
This article is provided for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for questions about diagnosis, treatment, or your personal health.